 |
|
| node: | Re: O rakovine a falošnej nádeji – 2. časť (Ohlasy a komentáre) |
| template: | 4 |
| parent: | O rakovine a falošnej nádeji – 2. časť (Ohlasy a komentáre) |
| owner: | Tomáš, to sa vie |
| viewed by: | |
| created: | 28.08.2013 - 17:00:55 |
|
cwbe coordinatez: 101 63539 63556 63998 7306631 7306649 ABSOLUT KYBERIA |
| permissions | |
| you: | r, |
| system: | public |
| net: | yes |
total descendants::2
total children::1
ad intravenozny vit c a rakovina:
One thing is fairly clear from the data reported thus far, even Mark Levine’s data and his calls to “revisit” the question of vitamin C and cancer with an “open mind”: If high dose intravenous ascorbate has antitumor activity in humans, that activity is almost certainly quite modest at best, and to achieve even such modest antitumor activity definitely requires incredibly high doses of ascorbate. Once again, I point out that any other experimental drug requiring such high plasma concentrations and high doses to achieve such a modest antitumor effect would probably garner very little interest from anyone, even if it were a potentially patentable product of big pharma. It’s possible that high dose IV ascorbate might ultimately find its way into the armamentarium of science-based oncology, but it’s very unlikely ever to become a mainstay of treatment for any malignancy. It’s just too wimpy.
autor D. Gorski
cely clanok http://www.sciencebasedmedicine.org/high-dose-vitamin-c-and-cancer-has-linus-pauling-been-vindicated/
One thing is fairly clear from the data reported thus far, even Mark Levine’s data and his calls to “revisit” the question of vitamin C and cancer with an “open mind”: If high dose intravenous ascorbate has antitumor activity in humans, that activity is almost certainly quite modest at best, and to achieve even such modest antitumor activity definitely requires incredibly high doses of ascorbate. Once again, I point out that any other experimental drug requiring such high plasma concentrations and high doses to achieve such a modest antitumor effect would probably garner very little interest from anyone, even if it were a potentially patentable product of big pharma. It’s possible that high dose IV ascorbate might ultimately find its way into the armamentarium of science-based oncology, but it’s very unlikely ever to become a mainstay of treatment for any malignancy. It’s just too wimpy.
autor D. Gorski
cely clanok http://www.sciencebasedmedicine.org/high-dose-vitamin-c-and-cancer-has-linus-pauling-been-vindicated/